Beta 1 Integrin as a Novel Predictive Biomarker and a Target in HER-2 Positive Trastuzumab Resistant Women with Breast Cancer
| Period from: | 2008-12-01 to 2010-05-31 |
| Principal Investigators: | Dr.Bassam Abdulkarim |
| Co-Investigators: | Raymond Lai; John Mackay; Siham Sabri; Jean Deschenes; David Murray |
| Institution: | Alberta Cancer Board |
| Department: | Cross Cancer Institute |
| Partner: | Canadian Partnership Against Cancer Corporation |
| Program: | Pilot Research Project |
| Abstract: |
This project seeks to improve the effectiveness and targeting of Trastuzumab (Tz) therapy for HER-2-positive MBC patients. Although the use of Tz with chemotherapy has been shown to increase both survival and response rate, 50% of patients do not respond to treatment and most patients rapidly develop Tz resistance within one year.
Our research project will unravel the mechanisms of Tz resistance and lead to the validation of a novel target in HER-2 positive breast cancer patients to pursue combined targeted therapy using Tz and anti-Beta (ß)1Integrin for patients overexpressing both ß1Integrin and HER-2. It is also crucial to establish a novel predictive test of Tz efficacy and, thereby, strictly target patients who will benefit from Tz while greatly improving the pharmacoeconomics of this treatment.
The ultimate goal is to increase the effectiveness of Tz as a therapy. The current project seeks to confirm the role of Beta (ß)1 Integrin in Tz resistance, and provide a greater understanding of the mechanisms of both primary and acquired resistance. We will use cell lines and animal model experiments to confirm the role of Beta (ß)1 Integrin.
|
| Funding Information: | |
| 2008-2009 | $39,778 |
| 2009-2010 | $119,333 |
| 2010-2011 | $19,889 |
| TOTAL | $179,000 |
|
 |
